Lead TCR Therapeutic Program
Solid Tumors
Pre-clinicalActive
Key Facts
About 3T Biosciences
3T Biosciences is a private, clinical-stage biotech based in South San Francisco, founded in 2015. The company's core innovation is the 3T-TRACE platform, which integrates high-diversity experimental libraries with machine learning to discover novel tumor targets and design TCR-based therapeutics, addressing a major bottleneck in solid tumor treatment. With a pipeline advancing toward first-in-human studies, the company is building its clinical operations team and positioning itself in the competitive cell therapy space. Key risks include platform validation, clinical execution, and competition from established players and other novel modalities.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| DM001 | Domabio | Phase 1 |
| DM002 | Domabio | Phase 1 |
| DM005 | Domabio | Phase 1 |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| CAR-T Solid Tumor Program | Carina Biotech | Phase 1/2a |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |